Autolus Therapeutics plc ADR
Autolus Therapeutics plc ADR (AUTL) Option Chain
Read more
Tracking the AUTL option chain helps you see every strike and expiry on Autolus Therapeutics plc ADR in one view, so you can quickly identify contracts that fit your thesis and your risk. It lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of AUTL options activity at a glance. Use our scanner to monitor the AUTL option chain in real time and filter for the trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For AUTL stock options, the chain shows call and put data side by side, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading it well means looking beyond the last price. Implied volatility by strike, volume to open interest ratios, and bid ask spreads all show where AUTL options are being actively traded, and where they are not.
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma.
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 2.25 | 21 | 0 | 0.17 | 0.48 | 0.15 | 1.15 | 0.50 | -52.83 | — | 1.00 | 0.00 | 1.00 | 0 | 0 | 97.76 |
| 50.12 | 6 | 0 | 0.75 | 0.00 | — | 0.75 | 1.00 | -5.66 | — | 0.10 | 0.02 | 0.08 | 0 | 0 | 49.88 |
| 88.06 | 8 | 0 | 1.00 | 0.00 | — | 1.00 | 1.50 | +41.51 | 0.05 | 0.70 | 0.52 | -0.15 | 20 | 17 | 11.94 |
| 97.79 | 732 | 0 | 0.05 | 0.00 | — | 0.05 | 2.00 | +88.68 | 0.45 | 1.45 | 1.02 | -0.07 | 0 | 0 | 2.21 |
| 99.61 | 100 | 0 | 1.20 | 0.00 | — | 1.20 | 2.50 | +135.85 | — | 4.00 | 1.52 | 2.48 | 0 | 0 | 0.39 |
As of Nov 18, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank99.60% High
- Market cap (M$)282
- 52 weeks high-58.91%
- 52 weeks low-0.93%
- Analyst recommendationStrong Buy
1.00 - Target price$8.10
726.87% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-10
- P/E—
- Future P/E—
- EPS (ttm)-0.96
- EPS growth next 5 years25.74%
As of Nov 18, 2026